Endocrine Abstracts

Aims: Spain has been one of the worst affected countries by the COVID-19 pandemic. A very strict lockdown at home was imposed with a tough restriction of mobility. We aimed to evaluate the impact of this exceptional scenario on glucose profile of patients with type 1 diabetes (T1D) prone to hypoglycemia using standalone continuous glucose monitoring.

Methods: Patients with T1D prone to hypoglycemia using multiple daily injections and either a Dexcom G5 or a Free Style Libre CGM systems for at least 6 months under the funding of National Health Service were included in an observational, retrospective study. Data were collected in two periods: pre-lockdown (PL), February 23rd–March 7th and within lockdown (WL), April 1st–14th 2020. The primary outcome was the difference in the proportion of time in target glucose range of 70–180 mg/dl (TIR). Additional glucometric data were also analysed.

Results: 92 patients were included: 40 women, age 42.8 ± 3.9 years, disease duration of 23.1 ± 12.6 years. Seventeen patients used Dexcom G5 and 75 Free Style Libre. TIR 70–180 mg/dl (59.3 ± 16.2 vs 62.6 ± 15.2%), time >180 (34.4 ± 18.0 vs 30.7 ± 16.9%), >250 (11.1 ± 10.6 vs 9.2 ± 9.7%) and Glucose Management Indicator (7.2 ± 0.8 vs 7.0 ± 0.8) significantly improved (PL vs WL, respectively, P < 0.05). Time in hypoglycemia remained unchanged.

Conclusions: Lockdown conditions imposed by the COVID-19 pandemic may be managed successfully in terms of glycemic control by population with DT1 prone to hypoglycemia using CGM. The strict daily routine at home could probably explain the improvement in the time in glycemic target without increasing the time in hypoglycemia.